文献速递中毒与环境急症重症综合管理与镇静镇痛

新鲜冰冻血浆作为急性有机磷中毒辅助治疗的系统评价与荟萃分析

Fresh frozen plasma as an adjunctive therapy in acute organophosphate poisoning: a systematic review and meta-analysis.
PubMed 文献 · Clin Toxicol (Phila) · 2026-09-22
一句话结论辅助性新鲜冰冻血浆可能减少机械通气需求和缩短住院时间,但未显著降低死亡率,证据确定性低至极低,不足以支持常规使用。

该系统评价与荟萃分析遵循PRISMA指南,检索多个数据库至2025年7月,纳入7项随机对照试验(总n=421),比较辅助性新鲜冰冻血浆与单纯标准治疗在急性症状性有机磷中毒住院患者中的疗效与安全性。主要终点死亡率在6项研究(n=369)中无统计学显著降低(RR 0.58;95%CI 0.27-1.25;I2=17%;极低确定性)。新鲜冰冻血浆与住院时间缩短(MD -1.89天;95%CI -3.68至-0.11;I2=77%;极低确定性)和机械通气需求减少(RR 0.80;95%CI 0.66-0.96;I2=9%;低确定性)相关。非严重不良事件不常见,主要为荨麻疹(RR 3.59;95%CI 0.60-21.44;低确定性)。结论认为辅助性新鲜冰冻血浆可能提供 modest 益处,但证据确定性低至极低,不足以支持常规使用,需更大规模高质量RCT。

要点

  • 在急性症状性有机磷中毒住院患者中,辅助性新鲜冰冻血浆未显著降低死亡率(RR 0.58;95%CI 0.27-1.25;极低确定性)。
  • 辅助性新鲜冰冻血浆与机械通气需求减少相关(RR 0.80;95%CI 0.66-0.96;低确定性)。
  • 辅助性新鲜冰冻血浆与住院时间缩短相关(MD -1.89天;95%CI -3.68至-0.11;极低确定性)。
  • 非严重不良事件不常见,主要为荨麻疹(RR 3.59;95%CI 0.60-21.44;低确定性)。
  • 当前证据确定性低至极低,不足以支持常规使用新鲜冰冻血浆作为辅助治疗。

适用人群与场景

  • 住院的急性症状性有机磷中毒患者,比较辅助性新鲜冰冻血浆与单纯标准治疗。
  • 纳入随机对照试验;排除人群原文未提及。

诊断标准与关键阈值

  • 原文未提及

处置流程与药物剂量

  • 原文未提及

红旗征与不能漏的情况

  • 原文未提及

研究设计与关键结果

  • 研究类型:系统评价与荟萃分析,纳入7项随机对照试验,总样本量n=421。
  • 主要终点死亡率:6项研究(n=369)荟萃分析显示辅助性新鲜冰冻血浆无统计学显著死亡率降低(RR 0.58;95%CI 0.27-1.25;I2=17%;极低确定性)。
  • 次要终点住院时间:辅助性新鲜冰冻血浆与住院时间缩短相关(MD -1.89天;95%CI -3.68至-0.11;I2=77%;极低确定性)。
  • 次要终点机械通气需求:辅助性新鲜冰冻血浆与机械通气需求减少相关(RR 0.80;95%CI 0.66-0.96;I2=9%;低确定性)。
  • 次要终点阿托品需求量:数据报告异质性大,不适合荟萃分析。
  • 不良事件:非严重不良事件不常见,主要为荨麻疹(RR 3.59;95%CI 0.60-21.44;低确定性)。

证据类型、等级与局限

  • 证据类型:系统评价与荟萃分析,纳入7项随机对照试验。
  • 证据等级:使用GRADE评估,主要终点死亡率为极低确定性,机械通气需求为低确定性,住院时间为极低确定性,荨麻疹为低确定性。
  • 局限:试验数量少、方法学异质性、研究总体偏倚风险高;证据确定性低至极低,不足以支持常规使用。

对床旁实践的改变

  • 当前证据不足以支持在急性有机磷中毒患者中常规使用新鲜冰冻血浆作为辅助治疗。
  • 辅助性新鲜冰冻血浆可能减少机械通气需求和缩短住院时间,但死亡率获益未证实,需个体化权衡。
  • 需更大规模高质量随机对照试验来明确其临床作用。

指南或共识出处

  • 原文未提及

以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。

英文原文(摘要)· 点击展开

INTRODUCTION: Organophosphate poisoning is a leading cause of pesticide-related morbidity and mortality globally, particularly in low- and middle-income countries. Standard treatment with atropine and oximes has well-recognized limitations, and fresh frozen plasma has been proposed as an adjunctive therapy through exogenous butyrylcholinesterase supplementation. However, its clinical efficacy remains uncertain. This systematic review and meta-analysis evaluate the efficacy and safety of fresh frozen plasma as an adjunctive therapy in acute organophosphate poisoning.

METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines. We searched PubMed, Cochrane Library, Science Direct, Google Scholar, Europe PMC, Trip Database, LILACS, IMSEAR, and trial registries from inception to July 2025 for randomized controlled trials comparing adjunctive fresh frozen plasma with standard therapy alone in hospitalized patients with acute symptomatic organophosphate poisoning. Pairs of reviewers independently screened studies, extracted data, assessed risk of bias using the Cochrane RoB2 tool, and evaluated certainty of evidence using GRADE. The primary outcome was mortality. Secondary outcomes included length of hospital stay, need for mechanical ventilation, atropine requirements, and adverse events.

RESULTS: Seven randomized controlled trials (total n = 421) were included. Meta-analysis of six studies (n = 369) showed no statistically significant mortality reduction with fresh frozen plasma (risk ratio 0.58; 95% confidence interval 0.27-1.25; I2 = 17%; very low certainty). Fresh frozen plasma was associated with a shorter hospital stay (mean difference -1.89 days; 95% confidence interval -3.68 to -0.11; I2 = 77%; very low certainty) and a reduced need for mechanical ventilation (risk ratio 0.80; 95% confidence interval 0.66-0.96; I2 = 9%; low certainty). Atropine requirement data were heterogeneously reported and not suitable for meta-analysis. Non-severe adverse events were infrequent, primarily urticaria (risk ratio 3.59; 95% confidence interval 0.60-21.44; low certainty).

DISCUSSION: The available evidence suggests that adjunctive fresh frozen plasma may reduce the need for mechanical ventilation and shorten hospital stay in acute organophosphate poisoning, but it did not demonstrate a significant mortality benefit. These findings are limited by the small number of trials, methodological heterogeneity, and a generally high risk of bias across studies.

CONCLUSION: Adjunctive fresh frozen plasma may offer modest benefits in reducing ventilator dependence and hospitalization duration in acute organophosphate poisoning, with a manageable safety profile. However, current evidence is of low to very low certainty and insufficient to support routine use. Larger, high-quality randomized controlled trials are needed to definitively establish its role in clinical management.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. De Santi O, Orellana MJ, Di Niro CA, et al. Fresh frozen plasma as an adjunctive therapy in acute organophosphate poisoning: a systematic review and meta-analysis. Clin Toxicol (Phila). 2026. PMID: 42770382. doi:10.1080/15563650.2026.2732065

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。